Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02679625
Other study ID # IRB #14H-136004
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 1, 2014
Est. completion date December 1, 2019

Study information

Verified date April 2020
Source Olive View-UCLA Education & Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Accurate assessment of fluid responsiveness (FRes) is central to guiding fluid management in septic and critically ill patients. As evidence accumulates that both inadequate and excessive fluid resuscitation are associated with increased morbidity and mortality, it is simultaneously becoming increasingly clear that current widely used methods to predict FRes are of questionable accuracy. The optimal technique to predict FRes would be a non-invasive point-of-care test with not only a high degree of accuracy, but also one which requires minimal training to perform correctly and may be easily performed repeatedly for serial evaluation of FRes during the ongoing management of the critically ill patient.

To date, three major ultrasonographic modalities have emerged as viable candidates for the bedside assessment of FRes: 1) measurement of dynamic changes in inferior vena caval diameter (IVC-CI), 2) measurement of dynamic changes in peripheral arterial waveform derived variables (PA Doppler), and 3) echocardiographic measurement of dynamic changes in left ventricular outflow tract waveform derived variables (LVOT Doppler). In this study, the investigators will perform the first direct comparison of techniques representing all three of the above modalities in the prediction of FRes against a non-invasive bioreactance cardiac output monitor (the Cheetah NICOM™), which has been extensively validated against gold-standard invasive methods of cardiac output measurement. The investigators will compare the accuracy of these modalities in both spontaneously breathing and mechanically ventilated patients using passive leg raise testing (PLR) as a surrogate for volume challenge. In addition, the investigators will also elicit information from the treating physician(s) on their clinical assessment of FRes.

The investigators will recruit adult patients in the ED and ICU with sepsis, who have received an initial bolus of 20-30 cc/kg of IV fluid, and can tolerate the PLR and US procedures. Prior to US and NICOM measurement, investigators will ask the attending physician managing the patient regarding their assessment of the their fluid status. Then, separate investigators will perform US and NICOM measurements independently to ensure blinding. NICOM data, which has been well validated in septic patients, will be shared with the attending physician. They will then be asked if this new data will change management.


Description:

This is a diagnostic accuracy study comparing selected ultrasound techniques to a well validated standard for predicting fluid responsiveness in septic patients (NICOM). The primary outcomes will be reported in sensitivity, specificity, positive predictive value, negative predictive value, likelihood ratios, and receiver operating characteristic curves.

The timeframe for measurement is within 72 hours of the subjects' admission. Determination of the outcome (i.e., whether a subject is fluid responsive) is based upon the data generated by the NICOM device. The NICOM generates data within 5 minutes of assessment. The ultrasound modalities to be studied will generate data within 5 minutes of assessment as well. The US data will be compared to the NICOM data to generate the statistics listed in this protocol. There is no further planned follow-up for the subjects.

1. The investigators will compare the ability of dynamic changes in inferior vena caval diameter (IVC-CI), dynamic changes in peripheral arterial waveform derived variables (PA Doppler), and dynamic changes in left ventricular outflow tract waveform derived variables (LVOT Doppler) to detect fluid responsiveness (FRes) relative to FRes as assessed by bioreactance cardiac output monitoring before and after passive leg raise (PLR).

Hypothesis: PA Doppler and LVOT Doppler will have superior sensitivity and specificity to predict FRes in comparison to IVC-CI.

2. The investigators will evaluate data acquisition duration and data acquisition failure rate of IVC-CI, PA Doppler, and LVOT Doppler. Hypothesis: PA Doppler will have shorter data acquisition durations in comparison to LVOT velocity variation and IVC-CI.

Hypothesis: PA Doppler will have lower data acquisition failure rates in comparison to LVOT velocity variation and IVC-CI.

3. The investigators will compare the ability of IVC-CI, PA Doppler, and LVOT Doppler to predict FRes in comparison to FRes as predicted by clinical judgment.

Hypothesis: PA Doppler and LVOT Doppler will have superior sensitivity and specificity to predict FRes in comparison to clinical judgment.

4. The investigators will evaluate the ability of dynamic changes in PA corrected flow times (cFT) to detect FRes relative to FRes as assessed by bioreactance cardiac output monitoring before and after PLR. Hypothesis: cFT will have greatest sensitivity and specificity to predict FRes at a Δflow time threshold of ≥15% after PLR.

Hypothesis: At a Δflow time threshold of ≥15%, cFT will have superior sensitivity and specificity to detect FRes in comparison to IVC-CI.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date December 1, 2019
Est. primary completion date November 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria:

- Subjects presenting to the ED will be screened in accordance with the Olive View Medical Center Sepsis Waiver, and subjects meeting two of the following four criteria will be eligible for inclusion in the study: Temperature >38/100.4 or <36/96.8, heart rate >90, respiratory rate >20 or PaCO2<32, and WBC >12K or <4K or > 10% bands (neutrophils). The clinical team will be contacted regarding patients identified based on this initial screening, and if the patient is determined to have a suspected infection and a fluid bolus is planned, the patient will be enrolled in the study if they meet the following criteria:

- Adult between the age of 18 to 90 years old;

- Not pregnant;

- Not using non-invasive positive pressure ventilation (CPAP or BiPAP);

- No history of heart, lung, and/or liver transplant;

- Not determined by the clinical team to be acutely unstable requiring immediate intervention at the time of data collection, and;

- No contraindications to a passive leg raise test (known or suspected cranio-cerebral or C-spine injury, venous thrombosis, orthopedic injury requiring immobilization or traction, or other contraindications as per clinical team).

Exclusion Criteria:

- Pregnant;

- Using non-invasive positive pressure ventilation (CPAP or BiPAP);

- Presence of or suspected elevated intracranial pressure;

- Presence of central venous catheters or other medical devices that prevent the use of bedside ultrasound;

- History of heart, lung, and/or liver transplant;

- History of critical aortic stenosis or severe aortic insufficiency;

- Determined by the clinical team to be acutely unstable and requiring immediate intervention at the time of study enrollment or data collection or;

- Has a contraindication to passive leg raise maneuver, e.g. known cervical spinal injury, deep venous thrombosis, orthopedic injury requiring immobilization or traction.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Ultrasound and NICOM
All patients enrolled will have all three ultrasound-based modalities for fluid responsiveness performed, as well as have NICOM data to serve as the comparison standard.

Locations

Country Name City State
United States Olive View-UCLA Sylmar California

Sponsors (2)

Lead Sponsor Collaborator
Olive View-UCLA Education & Research Institute University of California, Los Angeles

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fluid responsiveness (measured as cardiac output change, velocity time integral change, or maximal velocity change of greater than 10%, with either passive leg raise maneuver or respiratory variability). FRes is defined as the ability to predict that subjects who receive a small bolus of 250-500 ml of intravenous fluid will have a rise in their cardiac output or stroke volume of greater than 10%. FRes is a unit-less measurement, as it reflects the percent change in either stroke volume, cardiac index/output, IVC diameter, VTI, or Vmax, as a result of either a passive leg raise or the respiratory cycle. The criterion standard for FRes in this study will be assessed with the NICOM machine. Assessments of FRes using ultrasound-based measures (LVOT, carotid, femoral, and IVC) will be compared to the NICOM-determined assessment of FRes. Analysis is directed at how well the ultrasound-based definitions of FRes perform compared to the NICOM-based assessment. Fluid responsiveness is assessed in a three minute interval using the study gold standard, the NICOM. FRes assessment using ultrasound will be performed during this time. One set of measurements will be obtained upon subject admission to the ED or ICU.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3

External Links